Showcases Stock ranks Forex

Bristol-Myers Squibb Company (BMY)
63.05  0.21 (0.33%) 11-27 13:00
Open: 63.28 Pre. Close: 62.84
High: 63.69 Low: 62.88
Volume: 4,098,551 Market Cap: 142,477M
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration agreement with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc.; and a discovery collaboration with Insitro, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 63.574 - 63.909 63.909 - 64.194
Low: 61.404 - 61.785 61.785 - 62.109
Close: 62.213 - 62.861 62.861 - 63.412
Stock Technical Analysis
Target: Six months: 77.36
One year: 90.35
Support: Support1: 60.37
Support2: 56.75
Resistance: Resistance1: 66.23
Resistance2: 77.36
Pivot: 63.18
Moving Averages: MA(5): 62.53
MA(20): 62.81
MA(100): 60.71
MA(250): 60.71
MACD: MACD(12,26): 0.50
Signal(12,26,9): 0.63
%K %D: %K(14,3): 38.72
%D(3): 36.53
RSI: RSI(14): 54.30
52-Week: High: 68.34
Low: 45.76
Change(%): 9.8
Average Vol(K): 3-Month: 1057988
10-Days: 917442
Price, MAs and Bollinger Bands
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.

BMY has closed above bottom band by 46.4%. Bollinger Bands are 22.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sat, 28 Nov 2020
Societe Generale Suggested "a Buy" Rating to Bristol-Myers Squibb Company (NYSE:BMY) stock - BOV News

Fri, 27 Nov 2020
Analysts Mean recommendation for Bristol-Myers Squibb Company (BMY) was 1.90: Is this the key time? - The InvestChronicle

Wed, 25 Nov 2020
Bristol-myers Squibb Company (BMY) EVP, Chief Information Officer Autenried Paul Von Sold $1. ... - Yahoo Finance

Tue, 24 Nov 2020
Do Hedge Funds Love Bristol Myers Squibb Company (BMY) As Much As Buffett Does? - Yahoo Finance

Tue, 24 Nov 2020
Is Bristol Myers Squibb Stock a Buy? - Motley Fool

Mon, 23 Nov 2020
Bristol-myers Squibb Company (BMY) EVP, Research & Early Dev. Rupert Vessey Sold $3. ... - Yahoo Finance

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 2260.00
Shares Float (M) 2260.00
% Held by Insiders 0.08
% Held by Institutions 76.02
Shares Short (K) 15710
Shares Short Prior Month (K) 11620
Stock Financials
EPS -0.020
Book Value (p.s.) 22.200
Profit Margin -0.11
Operating Margin 20.04
Return on Assets (ttm) 5.4
Return on Equity (ttm) -0.1
Qtrly Rev. Growth 75.5
Gross Profit (p.s.) 8.376
Sales Per Share 17.434
EBITDA (p.s.) 7.442
Qtrly Earnings Growth 38.40
Operating Cash Flow (M) 12420.00
Levered Free Cash Flow (M) 14970.00
Stock Valuation
PE Ratio -3152.50
PEG Ratio 0.84
Price to Book value 2.84
Price to Sales 3.62
Price to Cash Flow 11.47
Stock Dividends
Dividend 1.800
Dividend Yield 0.03
Dividend Growth 1.800

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator